uniQure (NASDAQ:QURE) Trading 5.4% Higher – Time to Buy?

uniQure (NASDAQ:QURE) shares rose 5.4% during trading on Thursday . The stock traded as high as $12.62 and last traded at $12.75. Approximately 393,383 shares traded hands during trading, a decline of 62% from the average daily volume of 1,027,320 shares. The stock had previously closed at $12.09.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on QURE shares. Cantor Fitzgerald lifted their price objective on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, December 10th. StockNews.com raised uniQure to a “sell” rating in a research report on Wednesday, February 5th. Guggenheim reissued a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Leerink Partners boosted their target price on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. Finally, Mizuho upped their target price on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 19th. One analyst has rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, uniQure presently has a consensus rating of “Moderate Buy” and an average target price of $38.89.

uniQure Trading Down 2.2 %

The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The company has a market capitalization of $596.13 million, a P/E ratio of -2.47 and a beta of 0.38. The company has a 50-day simple moving average of $14.48 and a 200 day simple moving average of $9.96.

Insider Buying and Selling

In related news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Christian Klemt sold 10,438 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $107,407.02. Following the completion of the transaction, the chief financial officer now directly owns 217,730 shares of the company’s stock, valued at approximately $2,240,441.70. This trade represents a 4.57 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 96,044 shares of company stock valued at $1,001,040. 4.74% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Twin Tree Management LP bought a new stake in uniQure in the 4th quarter valued at $77,000. FNY Investment Advisers LLC acquired a new stake in shares of uniQure during the 4th quarter valued at about $88,000. RTW Investments LP bought a new stake in uniQure in the third quarter valued at about $49,000. ADAR1 Capital Management LLC acquired a new position in uniQure in the fourth quarter worth about $177,000. Finally, Atria Investments Inc acquired a new position in uniQure in the third quarter worth about $53,000. 78.83% of the stock is owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.